Fragmin® is a low molecular weight heparin with a number of indications which include the extended treatment of Cancer Associated Thrombosis in solid tumour patients
Unstable Angina and NSTEMI: Risk Factors
If UA and NSTEMI are untreated after a firm diagnosis, the prognosis is poor and mortality high, particularly in patients with myocardial damage1
•Appropriate triage, risk assessment and timely use of acute pharmacological and invasive interventions is critical in preventing future cardiovascular events (MI, stroke, repeat revascularisation and death)
*Including, but not limited to: congestive cardiac failure (NYHA class III or IV), acute respiratory failure or acute infection, who also have a predisposing risk factor for VTE such as age over 75 years, obesity, cancer or previous history of VTE.~
†In patients with chronic renal insufficiency or acute renal failure.
"By clicking "confirm" to create an account, you confirm that the information you have provided above is correct, and you agree to (i) Pfizer’s processing of your personal data, including its transfer internationally and to third parties, in accordance with the Pfizer Privacy and Cookie Policy; and (ii) Pfizer’s Website Terms of Use."